2023/10/12 Receives the notice of exercising the Option in the license agreement of ALA-1000 and related products from INDIVIOR UK LIMITED Post author:alarpharm Post published:12 . 10 . 2023 Post category:Media releases You Might Also Like 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2023/08/02 ALA-3000 has received an Intention to Grant (IGRA) from European Patent Office (EPO) after examination. (Patent Application No. 20739053.5) 10 . 8 . 2023 2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021 2021/09/03 ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO), Application No. 106131215. 7 . 9 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2023/08/02 ALA-3000 has received an Intention to Grant (IGRA) from European Patent Office (EPO) after examination. (Patent Application No. 20739053.5) 10 . 8 . 2023
2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021
2021/09/03 ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO), Application No. 106131215. 7 . 9 . 2021
